S&P 500   3,102.13 (-0.05%)
DOW   27,797.16 (+0.11%)
QQQ   201.08 (-0.31%)
CGC   18.40 (-9.31%)
BABA   184.67 (-0.10%)
T   37.77 (+0.45%)
BAC   33.08 (+0.73%)
DIS   147.72 (+0.56%)
S&P 500   3,102.13 (-0.05%)
DOW   27,797.16 (+0.11%)
QQQ   201.08 (-0.31%)
CGC   18.40 (-9.31%)
BABA   184.67 (-0.10%)
T   37.77 (+0.45%)
BAC   33.08 (+0.73%)
DIS   147.72 (+0.56%)
S&P 500   3,102.13 (-0.05%)
DOW   27,797.16 (+0.11%)
QQQ   201.08 (-0.31%)
CGC   18.40 (-9.31%)
BABA   184.67 (-0.10%)
T   37.77 (+0.45%)
BAC   33.08 (+0.73%)
DIS   147.72 (+0.56%)
S&P 500   3,102.13 (-0.05%)
DOW   27,797.16 (+0.11%)
QQQ   201.08 (-0.31%)
CGC   18.40 (-9.31%)
BABA   184.67 (-0.10%)
T   37.77 (+0.45%)
BAC   33.08 (+0.73%)
DIS   147.72 (+0.56%)
Log in

Obseva Stock Price, Forecast & Analysis (NASDAQ:OBSV)

$2.83
+0.12 (+4.43 %)
(As of 11/22/2019 11:08 AM ET)
Today's Range
$2.74
Now: $2.83
$2.88
50-Day Range
$2.48
MA: $6.30
$8.00
52-Week Range
$2.37
Now: $2.83
$15.93
Volume2,480 shs
Average Volume304,118 shs
Market Capitalization$128.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.54 per share

Profitability

Net Income$-76,720,000.00

Miscellaneous

Employees43
Market Cap$128.71 million
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.


Obseva (NASDAQ:OBSV) Frequently Asked Questions

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) released its earnings results on Thursday, November, 7th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.19. View Obseva's Earnings History.

When is Obseva's next earnings date?

Obseva is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Obseva.

What price target have analysts set for OBSV?

4 analysts have issued 12-month price objectives for Obseva's shares. Their forecasts range from $4.00 to $44.00. On average, they anticipate Obseva's stock price to reach $28.67 in the next year. This suggests a possible upside of 913.0% from the stock's current price. View Analyst Price Targets for Obseva.

What is the consensus analysts' recommendation for Obseva?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.

What are Wall Street analysts saying about Obseva stock?

Here are some recent quotes from research analysts about Obseva stock:
  • 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (11/9/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019)

Has Obseva been receiving favorable news coverage?

News articles about OBSV stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obseva earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Obseva.

Who are some of Obseva's key competitors?

What other stocks do shareholders of Obseva own?

Who are Obseva's key executives?

Obseva's management team includes the folowing people:
  • Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
  • Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
  • Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
  • Mr. Mario Vincent Corso, Sr. Director of Investor Relations
  • Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)

When did Obseva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are Obseva's major shareholders?

Obseva's stock is owned by many different of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.09%).

Which institutional investors are buying Obseva stock?

OBSV stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $2.83.

How big of a company is Obseva?

Obseva has a market capitalization of $128.71 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva.

What is Obseva's official website?

The official website for Obseva is http://www.obseva.com/.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]


MarketBeat Community Rating for Obseva (NASDAQ OBSV)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  475
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel